Russian tax service to tighten control of foreign pharma firms on domestic market

4 April 2017

Global drugmakers operating in Russia will be obliged to transfer information on the price of their drugs to a single information system operated by the Russian Federal Tax Service, as part of the new state strategy for drugs’ labeling in the Russian pharmaceutical market, reports The Pharma Letter’s local correspondent.

In the meantime, according to producers, the transfer of the data will be associated with additional costs and bureaucratic hurdles for them, while any malfunctions of the system and delays in the transfer of the needed information may lead to suspicions by the Russian Federal Tax Service of underpaying taxes by the companies.

Currently foreign drugmakers operating in Russia are waiting for explanations from the Russian Federal Tax Service regarding with the new practice and its details.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK